Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH-Wildtype Glioblastoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Significance of CDKN2A Homozygous Deletion in Combination With Methylated MGMT Status for IDH-Wildtype Glioblastoma
Cancer Med 2021 Apr 10;[EPub Ahead of Print], Y Funakoshi, N Hata, K Takigawa, H Arita, D Kuga, R Hatae, Y Sangatsuda, Y Fujioka, A Sako, T Umehara, T Yoshitake, O Togao, A Hiwatashi, K Yoshimoto, T Iwaki, M MizoguchiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.